(SDB) is associated with adverse CVD risk factors and outcomes, including hypertension and myocardial infarction. [1] [2] [3] [4] [5] The prevalence of hypertension, atherosclerotic CVD, and myocardial infarction are elevated in individuals with diabetes and in individuals with sleep apnea. [5] [6] [7] [8] [9] Oxidative stress has been implicated as an important pathophysiologic mechanism contributing to CVD. 10 SDB is associated with an increase in oxidative stress that is due to repetitive episodes of hypoxia-reoxygenation. 11 The severity of oxidative stress and the adaptation to reduce that stress may explain differential susceptibility to atherosclerotic CVD 10,11 in individuals with SDB. 12-14 For example, functional polymorphisms in genes encoding antioxidant enzymes or proteins may be of particular importance in explaining susceptibility to CVD in individuals with SDB. Haptoglobin is an abundant serum protein for which there are 2 common alleles in humans, denoted 1 and 2. 15 Haptoglobin is an antioxidant as a direct result of its ability to prevent hemoglobin-driven oxidation, the potential for which may be increased in SDB due to hypoxia-reoxygenation injury to red blood cells. We and others have recently demonstrated that the antioxidant activity of haptoglobin differs between the different haptoglobin allelic variants. [16] [17] Haptoglobin type has recently been demonstrated to be a susceptibility gene for the development of CVD in individuals with diabetes, another disorder associated with increased oxidative stress. 18 Moreover, we have recently found in a series of patients with obstructive sleep apnea (OSA) that there is an apparent association between sleep apnea, haptoglobin phenotype, and CVD in individuals younger than 55 years of age. 19 We sought to confirm and extend these findings in the Sleep Heart Health Study (SHHS) by assessing the independent and joint effects of SDB and haptoglobin phenotype on the prevalence of cardiovascular disease.
INTRODUCTION
Background: Diabetes is an independent risk factor for cardiovascular disease, and there is growing evidence that sleep-disordered breathing also may increase the risk of cardiovascular disease. The mechanism responsible for increased susceptibility of people with diabetes to cardiovascular disease is thought to share several features with sleep-disordered breathing, notably increased oxidative stress. We recently demonstrated that a particular haptoglobin phenotype that is associated with differential antioxidant activity is an independent risk factor for cardiovascular disease in individuals with diabetes. We therefore sought to determine whether sleep-disordered breathing and cardiovascular disease are more strongly associated among people with the unfavorable haptoglobin phenotype. Methods: We tested this hypothesis in 2,612 middle-aged and older participants from the Sleep Heart Health Study. Haptoglobin phenotyping was performed by gel electrophoresis. Respiratory disturbance index was assessed by standard methods. Logistic regression analysis was performed to estimate the association between haptoglobin phenotype and cardiovascular disease, adjusting for known cardiovascular risk factors (age, sex, diabetes, smoking, lipid levels, and hypertension). Possible modification by haptoglobin phenotype of the association of sleep-disordered breathing with cardiovascular disease prevalence was explored by examining interaction terms. Results: We found no significant association between haptoglobin phenotype and prevalent cardiovascular disease in this cohort, nor were significant interactions found between haptoglobin phenotype and sleep-disordered breathing on the prevalence of cardiovascular disease. Conclusions: Sleep-disordered breathing did not appear to interact with haptoglobin phenotype in modifying the association with prevalent cardiovascular disease in the Sleep Heart Health Study. These findings could be due to the absence of association or to survivor bias in these cross-sectional analyses. 
RESEARCH DESIGN AND METHODS

The SHHS: Design and Parent Cohorts
The SHHS is a multicenter study designed to determine the cardiovascular consequences of SDB. The design and objectives of the SHHS, as well as detailed descriptions of its member cohorts, protocols, and quality-control procedures, have been previously reported. [20] [21] Briefly, the SHHS consists of an ethnically diverse cohort of men and women older than age 40 years who were members of "parent" cohort studies of CVD and respiratory disease. 22 The parent cohorts included in this report are the Cardiovascular Health Study, the Strong Heart Study, and the Framingham Heart Study. Detailed SHHS documentation, including protocols, data-collection forms, and manuals of operation, is available. 23 The SHHS protocol was approved by the Institutional Review Boards of the participating institutions, and informed consent was obtained from all participants.
Collection of Sleep Data
All participants underwent in-home overnight polysomnography using Compumedics PS-2 (Melbourne, Australia) equipment. Data were collected on 12 channels and included oximetry (Nonin Medical Inc., Plymouth, Minn), heart rate, chest-wall and abdominal movement (by respiratory inductance plethysmography), nasal/oral airflow (by thermocouple; ProTec, Woodinville, Wash), body position, electroencephalogram, electrooculogram, chin electromyogram, and electrocardiogram.
Technicians traveled to participants' homes in the evening to connect the polysomnography equipment, collect anthropometric data, administer questionnaires, and provide instructions to participants about handling the equipment. Technicians returned to participants' homes in the morning to collect the equipment. Upon returning to the field centers, technicians downloaded the sleep data and sent it to the polysomnography reading center for processing, where all studies were scored blinded.
Measurement of the Respiratory Disturbance Index During Sleep Disturbance
The respiratory disturbance index (RDI), defined as the number of apneas plus hypopneas per hour of sleep, was used to indicate the severity of SDB. Apneas were identified if the amplitude of the airflow decreased to below 25% of "baseline" amplitude (a period of regular breathing with stable oxygen levels) and if the change lasted for more than 10 seconds. Hypopneas were identified if airflow or respiratory effort decreased to less than 70% of baseline for at least 10 seconds but did not fall so low as to qualify as an apnea. In most analyses reported in this article, only events that were associated with at least a 4% desaturation level were included in the RDI (RDI4p). However, sensitivity analyses for definitions of RDI that were based on apneas and hypopneas that were defined using 2% and 3% desaturation levels, with and without electroencephalographic arousal, showed no significant differences from the analysis using RDI4p .
Definition of Prevalent CVD and Diabetes
Prevalent CVD was based on data reported by participants during the SHHS interview. These outcomes included history of hospitalized acute myocardial infarction, nonfatal coronary heart disease, stroke, angina, coronary artery bypass graft, and congestive heart failure. For the purposes of this report, CVD data were combined to form a single category representing individuals with prevalent CVD.
Because no blood was collected during the baseline SHHS exam, it was not possible to ascertain diabetes according to current clinical practice guidelines that require a fasting blood specimen. 24 Prevalent diabetes was therefore defined based on data on self-reported diabetes status and use of oral hypoglycemic medications and insulin that were collected during the SHHS interview. Limitations of self-reported diabetes data in the SHHS cohort have been discussed. 25 
Covariate Data
Blood pressure was measured before the polysomnography equipment was hooked up to the participant. Hypertension was examined as a categorical variable and defined as a systolic blood pressure or at least 140 or diastolic blood pressure of more than 90 mmHg or current treatment with antihypertensive medications. 26 Neck circumference was measured during the home visit. Data on smoking status were collected by questionnaire and examined as a dichotomous variable (ever vs never). Data on height, waist circumference, and lipoproteins were obtained from the parent cohorts.
Variables considered in this study included haptoglobin phenotype, cohort, sex, race, diabetes status, smoking status (ever vs never), and hypertension. Continuously distributed variables included age, BMI, and total cholesterol and triglyceride and high-density lipoproteins levels.
Statistical Analyses
The Hardy-Weinberg principle of population genetics is used to determine whether 2 alleles are in a balanced equilibrium, indicating a lack of survival benefit for 1 allele relative to the other. In order to determine whether our study population was in Hardy-Weinberg equilibrium, the actual distribution of the 3 haptoglobin types in this study was compared with the distribution of the 3 haptoglobin types expected if the population was in HardyWeinberg equilibrium according to the χ 2 test. 27 The distribution of missing information in phenotype or CVD across cohorts was examined. Basic characteristics were compared between groups with missing values in either phenotype or CVD and the counterparts with nonmissing values by χ 2 , t tests, or nonparametric tests. Further analysis was based on participants with both phenotype and CVD data.
χ 2 tests and 1-way analysis of variance were used to compare characteristics among phenotypes for continuous and categorical variables, respectively. Because of their nonnormal distribution, RDI variables were transformed using the formula log(RDI + 0.1), which achieved an approximately normal distribution. In some analyses, RDI was examined as a continuous variable, and in others it was divided into clinically defined cutpoints and examined as a categorical variable (< 5: category 0; 5-10: category 1; 10-15: category 2; and > 15: category 3). Log transformations also were used on high-density lipoproteins and triglyceride levels to meet the normality assumption of the analysis of variance.
Comparisons were further performed in subsets of data stratified by diabetes status, cohorts, and different RDI4p categorical vari-ables. The bivariate relationship between CVD and the categorical RDI4p variable was examined by χ 2 tests in both pooled data and subsets of data stratified by cohort, diabetes status, and phenotype. A Bonferroni adjustment was made for multiple comparisons. The 5% significance level adjusted for multiple comparisons was .05 divided by the total number of comparisons.
Univariate logistic regression models were used to assess the associations between CVD and each risk factor. Multivariable logistic regression models were then applied to estimate the associations between phenotype and CVD, while adjusting for other covariates. Models were conducted by stratifications of diabetes status, age category, and categorical RDI4p variables. In stratified models, covariates were adjusted except the variable of stratification. To explore the possibility of a nonlinear relationship with CVD and the possible interaction effects with haptoglobin phenotype on CVD, age (< 55, > 55 years), body mass index (< 18.5, < 25, < 30 kg/m 2 ), and RDI4p were examined as categorical variables. Possible modification effects of haptoglobin phenotype and diabetes on the association between RDI4p and CVD were explored using interaction terms. The deviance tests and Akaike Information Criterion statistic were used to select the best reduced model, but haptoglobin phenotype, RDI4p, and their interaction terms were kept in the model regardless of their statistical significance because they were the main variables of interest. The Hosmer-Lemeshow goodness-of-fit test was used to evaluate model fit. Model diagnostics were conducted on Pearson and deviance residuals.
Haptoglobin Phenotyping
Haptoglobin phenotyping was performed from 10 µL of EDTA plasma, as previously described, by polyacrylamide gel electrophoresis. 28 The Strong Heart Study, Cardiovascular Health Study, and Framingham Studies are all well-known, National Heart, Lung, and Blood Institute-funded, longitudinal studies that maintain banks of stored specimens for use in novel studies. Blood samples for haptoglobin typing used in this report were stored in -70C freezers until aliquotted for this study.
We have previously demonstrated that there is a 100% correspondence between the haptoglobin genotype as determined by polymerase chain reaction and the haptoglobin phenotype as determined by polyacrylamide gel electrophoresis. 29 Each of 3 possible combinations of the 2 haptoglobin alleles (homozygous for the 1 or 2 allele or heterozygous) was easily distinguished by gel electrophoresis because of the differing polymeric structure of the 3 haptoglobin allelic protein products. Each participant was assigned a haptoglobin phenotype of Hp 1-1, Hp 2-1, or Hp 2-2.
RESULTS
Definition of the Study Population
Of the 6,441 participants in the SHHS, 2,725 (42%) were members of cohorts (Strong Heart Study, Cardiovascular Health Study, Framingham) that agreed to participate in this ancillary study. Of these participants, 80 were missing information on baseline CVD status, and 37 had no information for haptoglobin phenotype (4 participants were missing both data elements). This analysis therefore consisted of 2,612 participants with both haptoglobin phenotype and CVD information (96% of the subjects from the participating cohorts). The distribution of covariates in the participants with available data did not significantly differ from the group with missing data.
Haptoglobin Phenotypes in the Study Population
The frequency of the 3 haptoglobin phenotypes in this sample was Hp 1-1: 480 (18.4%), Hp 2-1: 1,217 (46.6%), and Hp 2-2: 915 (35.0%). Consistent with previous reports from other studies, the distribution of the 3 haptoglobin phenotypes was not similar across the 3 parent cohorts (Table 1) . In each cohort, however, the distribution of the 3 haptoglobin phenotypes was in HardyWeinberg Equilibrium.
Clinical Characteristics of the Study Population Stratified by Haptoglobin Type
The distribution of categorical variables by haptoglobin phenotype is shown in Table 1 . A significant difference in the distribution of Hp phenotypes was found across the groups according to ethnicity, diabetes prevalence, and cohort. Of the 3 cohorts included in this analysis, the Strong Heart Study, which consists entirely of American Indians, had the highest prevalence of haptoglobin phenotype 1-1 (25% vs 16%-17%). African American, American Indian, and people with diabetes also had a high prevalence of haptoglobin phenotype 1-1. Additional analyses were conducted to examine the association between diabetes prevalence and haptoglobin phenotypes (not shown in tables). The Strong Heart Study cohort had the highest prevalence of diabetes (44% vs 6%-15%). The relationship between diabetes prevalence and haptoglobin phenotypes was examined within the strata of ethnicity. We observed no significant association between diabetes and haptoglobin phenotype in any ethnic group, but a marginal association was observed in American Indians (Fisher exact test, P value = .06).
The distributions of continuous variables stratified by haptoglobin phenotype are shown in Table 2 . Analyses of variance did not indicate a significant association between haptoglobin phenotype and RDI4p. However, significant differences were found in distributions of cholesterol, body mass index, and waist circumferences across the haptoglobin phenotypes. The study sample had a range of age from 40 to 100 years old, with similar distributions across haptoglobin phenotypes.
Association of Sleep Apnea with CVD
The relationship between individuals with the differing RDI4p categories and the prevalence of CVD is shown in Table 3 . As indicated in a previous analysis of the entire SHHS cohort, 6 a significant relationship was found between increasing RDI category and prevalence of baseline CVD. This relationship was consistent within each parent cohort and for RDI associated with 2% desaturations and RDI associated with 3% desaturation, which are less conservative definitions of SDB (data not shown).
Relationship Between Phenotype, CVD, and RDI
Both univariate and multivariable analyses of known conventional CVD risk factors demonstrated that age, sex, diabetes, smoking, hypertension, and hyperlipidemia were all significantly associated with prevalent CVD ( the Framingham and Cardiovascular Health Study cohorts and prevalent CVD, relative to membership in the Strong Heart Study cohort. We tested the association between SDB and prevalent CVD through both continuous RDI4p and categorical RDI4p, and consistent results were found. In this sample, we observed no association between haptoglobin phenotype and prevalent CVD, nor was the relationship between SDB and CVD modified by haptoglobin phenotype (Table 4) . We further examined the interaction effects between haptoglobin phenotype and diabetes and diabetes and SDB on prevalence of CVD by modeling the interaction terms, and no significant interaction effects were observed.
DISCUSSION
In a cross-sectional analysis of 2,612 members of the SHHS cohort, we observed no association between haptoglobin phenotype and prevalence of CVD. Severity of SDB did not influence this relationship. These cross-sectional results do not support the hypothesis that haptoglobin phenotype and increasing severity of SDB interact to increase the prevalence of CVD. Our results are inconsistent with previous longitudinal studies demonstrating a prospective relationship between haptoglobin phenotype and risk of CVD. Prospective studies have demonstrated an increased risk of incident CVD with Hp 1-1 in individuals without diabetes and an increased risk of incident CVD with Hp 2-2 in individuals with diabetes. 18, 30 In contrast, cross-sectional studies of predominately nondiabetic cohorts have shown different results from these prospective studies, with an increased prevalence of CVD associated with Hp 2-2. 30 Haptoglobin phenotype is known to vary dramatically between differing ethnic groups, and the haptoglobin-phenotype distribution within a given ethnic group is known to vary with age, presumably because of differential survivorship. 15, 31 However, diabetes is not known to be associated with haptoglobin type. 32 The apparent association of diabetes with haptoglobin type in the data set from the 3 combined cohorts can be attributed to the high prevalence of diabetes in the Strong Heart Study cohort (44% of participants in Strong Heart compared with 6%-15% in the other cohorts) and the higher incidence of Hp 1-1 in American Indians who comprise the Strong Heart Study. The apparent inconsistency between our cross-sectional and other longitudinal studies of haptoglobin and CVD may be due to survivorship bias, as evidenced by differences in the distribution of the 3 phenotypes as a function of age, and the lack of temporality between exposure and outcome that characterize cross-sectional studies. These potential biases may generate opposite results in cross-sectional analysis compared with longitudinal ones. For example, several cross-sectional studies have demonstrated an association of higher prevalence of Hp 2-2 and CVD. However, a recent prospective longitudinal study demonstrated that Hp 1-1 is associated with an increased incidence of cardiovascular mortality. 30 Cross-sectional studies of individuals with SDB also can be problematic because of differential survivorship. In people younger than 50 years of age, SDB has been demonstrated to be associated with a marked increase in cardiovascular mortality. However, in people older than age 50 years, this is not the case. 33 It is also possible that misclassification of both CVD and diabetes may have contributed to the negative outcome of this study. In this report, CVD was measured by clinical events rather than measures of subclinical disease, and diabetes was ascertained by self-report. However the objective of the SHHS is to examine the association between SDB and clinical CVD. The relationship between SDB and measures of subclinical CVD, such as carotid intima-media thickness or abnormalities in cardiac structure or function measured by echocardiography are both questions of great interest as well. Although a fasting blood draw was not included in the SHHS protocol, diabetes was ascertained multiple times by fasting blood draws in a number of the parent studies. However, as in most cohort studies, data are not available to ANOVA refers to analysis of variance; RDI4p, respiratory disturbance index associated with a 4% desaturation; HDL, high-density lipoproteins. The 5% significance level adjusted for multiple comparisons is 0.0063 (0.05/8). make a definitive distinction between type 1 and type 2 diabetes. Given this limitation, type 1 diabetes represents only 5% to 8% of all diabetes and is therefore unlikely to influence our results. Moreover, the mechanisms involving haptoglobin type, diabetes and CVD should apply similarly to all persons with chronic hyperglycemia. Thus, although there is likely some misclassification of diabetes status (ie, false negatives), the degree of this misclassification is much smaller than would be the case if the SHHS cohort were recruited de novo without a fasting blood draw, and misclassification of diabetes subtype is unlikely to influence our results from a mechanistic standpoint. A more likely explanation for the negative finding is that the study lacked power to detect such an association. Initial power calculations for this study were based on hypothesized distributions of haptoglobin phenotype and CVD that were not ultimately reflective of the true distributions once parent cohort specimens were obtained, thawed, and typed. Part of the reason for this is that the combination of cohorts that comprise SHHS contributed to difficulty in estimating these distributions.
We have recently found in an independent series of patients with obstructive sleep apnea in which there is an apparent association between sleep apnea, haptoglobin phenotype, and CVD in individuals younger than age 55 years. No association was found in SDB patients older than age 55 years. 19 The SHSS is predominately an older cohort and may therefore not be sufficiently powered to address the issue of an association between haptoglobin, CVD, and SDB in individuals younger than age 50 years. Furthermore, selection factors may lead to differences between a community sample, such as SHHS, and a sample of patients referred for obstructive sleep apnea.
Repetitive episodes of hypoxemia produced by SDB events may result in oxidative stress that could contribute to the pathogenesis of CVD. In this study, we examined a single marker of oxidative stress and its relationship to both SDB and CVD in a heterogeneous population. Although this study did not find a cross-sectional association between haptoglobin phenotype and CVD, or any modification by haptoglobin phenotype of the relationship between SDB and CVD, further prospective investigations designed specifically to address the role of innate susceptibility to oxidative stress and to the adverse effects of SDB are needed. The negative findings underscore the potential complexity of the pathobiologic pathways that may lead to atherosclerosis and the difficulty in delineating potential interactions among such pathways. Nonetheless, further assessment of the role of genetic polymorphisms may provide critical insight into determinants of susceptibility to CVD and may help identify which individuals with SDB may be most vulnerable to CVD.
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